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Role of NO on pressure-natriuresis in Wistar-Kyoto and spontaneously
hypertensive rats. We investigated the role of the endothelium-derived
relaxing factor nitric oxide (NO) on pressure-natriuresis in spontane-
ously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY) using in
vivo perfusion studies. Differences in the neural and hormonal back-
ground to the kidney were minimized by renal denervation and by
holding plasma vasopressin, aldosterone, corticosterone, and norepi-
nephnne levels constant by intravenous infusion. In WKY, elevation of
renal perfusion pressure (RPP) from 115 to 157 mm Hg increased
urinary sodium excretion 4.5 to 14.8 sEq/min/g kidney wt, and the
slope of its linear regression was 0.21 Eq/min/g kidney wt/mm Hg.
Infusion of an inhibitor of NO synthase, L-NMMA (1 mg/mm/kg),
lowered this slope (P < 0.05) but L-arginine (3 mg/mm/kg) did not
change it. By contrast, the impaired pressure-natriuresis response of
SHR was ameliorated by L-arginine (slope: 0.08 to 0.16; P < 0.05),
while L-NMMA did not blunt it further. GFR and renal plasma flow
(RPF) were well autoregulated in both strains, but L-NMMA lowered
RPF significantly (SHR: from 4.2 to 2.6 ml/min/g kidney wt; WKY: 4.5
to 2.5 ml/min/g kidney wt). Moreover, when infused simultaneously, all
these individual effects of L-NMMA and L-arginine were nullified.
These results suggest that NO plays an important role in the pressure-
natriuresis mechanism.
Abnormality in the pressure-natriuresis response has been
suggested as one of the crucial mechanisms in hypertension [1].
We have reported the importance of the intrarenal renin-
angiotensin system in spontaneously hypertensive rats [2], and
the prostaglandin system in DahI salt-sensitive rats [3] in their
abnormal response. These findings are consistent with several
other studies [4, 5], and various other humoral [6, 7] and neural
[8] factors are known to modulate this response.
Nitric oxide (NO), first described by Furchgott and Zawadzki
as endothelium-derived relaxing factor [9], is now considered to
be one of the major vasoactive substances released by the
endothelial cells. Although the participation of NO in the
pathogenesis of hypertension has been extensively studied,
moA of the studies were on its direct effect on the systemic
vasculature [10—14]. Recently, Zatz and De Nucci [15] demon-
strated that basal production of NO is an important regulator of
preglomerular afferent arteriolar tone, and Marsden, Brock and
Ballermann [16] reported that glomerular endothelial cells are
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able to release NO. These findings suggest that NO also plays a
significant role in the regulation of intrarenal hemodynamics.
Since much experimental evidence indicates that pressure-
induced natriuresis is closely associated with intrarenal hemo-
dynamics, it is logical to assume that NO is an effective
regulator of urine sodium excretion. However, there have been
only a few investigations concerning the effect of NO on the
pressure-natriuresis response [17], and to our knowledge, no
attempt has been made to characterize the participation of NO
in the abnormalities of the pressure-natriuresis response in
hypertensive rats.
The purpose of this study was, first, to investigate the role of
NO in the mechanism of the pressure-natriuresis response.
Second, the differential role of NO in both normotensive and
hypertensive rats was examined. Studies were performed under
conditions in which the neural and hormonal influences on the
kidney were minimized.
Methods
Animals
Experiments were carried out on 48 adult (12-week old) male
spontaneously hypertensive rats (Charles River Co., Kana-
gawa, Japan) and the same number of age and sex-matched
Wistar Kyoto rats (Charles River) weighing around 280 g. All
rats were fed on rat chow containing 0.38% sodium by weight
and were allowed to drink water ad libitum; however, they were
prohibited from feeding 12 hours before the surgical prepara-
tion.
Surgical preparation
The following preparation was performed according to the
previous reports [2, 3, 8]. The right kidney was removed seven
days before the experiment. Animals were anesthetized with an
intraperitoneal injection of mactin (100 mg/kg), and tracheoto-
mized to facilitate respiration. They were placed on a warm
plate to maintain body temperature at 37°C. The left carotid and
femoral arteries were cannulated (PE5O, Becton & Dickinson
Company, New Jersey, USA) to measure arterial blood pres-
sure above and below the left renal artery. Blood pressure was
monitored with a transducer (TP400T, Nihon Koden, Tokyo,
Japan) and an amplifier (AP6O1G, Nihon Koden), The left
external jugular vein was cannulated (PE5O) for the administra-
tion of saline containing 1% bovine serum albumin, 1% inulin,
0.1% para-aminohippurate (PAR), norepinephrine (1.0 ng/pi),
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aldosterone (0.2 ng/pi), hydrocortisone (0.2 tg/d), and vaso-
pressin (0.5 pg/pi). The infusion was started immediately after
the cannulation of the jugular vein at a rate of 100 d/min and
continued throughout the experiments (Microliter Syringe
Pump, model special, Harvard Apparatus, Massachusetts,
USA). With laparotomy, bilateral adrenal glands were removed
and the left kidney was denervated with a 10% solution of
phenol in ethanol. Another cannula (PE1O, Becton & Dickinson
Company) was placed in the left ureter for the collection of
urine. Two adjustable clamps were placed on the aorta, one
above and one below the left renal artery. Silk ligatures were
placed loosely around the superior mesenteric and celiac arter-
ies. An equilibrium period of 60 minutes was then allowed
before each of the following experiments.
Characterization of the pressure-natriuresis relationship of
SHR and WKY with N'-monomethyl-L-arginine (L-NMMA)
or L-arginine treatment
Twenty-four SHR and the same number of WKY rats were
used and they were divided into four groups (N = 6/group),
respectively.
L-NMMA groups (mean body weight: WKY285 5 g, SHR
281 5 g). After the equilibration period, a competitive
inhibitor of NO synthase, L-NMMA (1 mg/mm/kg, Sigma
Chemical Co., St. Louis, Missouri, USA) was added to the
saline vehicle and infused throughout the experiment. After a
15-minute lead-in, renal perfusion pressure (RPP) was lowered
to approximately 130 mm Hg in both SHR and WKY by
tightening the clamp above the renal artery. We initially in-
tended to lower RPP to approximately 110 mm Hg in WKY,
however, there was a significant rise in blood pressure within
five minutes of L-NMMA administration, and therefore we
could not stabilize the blood pressure level of WKY at 110 mm
Hg. After a 15-minute equilibration period, the first clearance
study was performed. This clearance study, as well as the
second and the third clearance studies, consisted of two 15-
minute clearance periods with 400 d of arterial blood sampling
at the midpoint of each period, and measurement of blood
pressure. Immediately after the each blood sampling, an equal
volume of arterial blood was transfused from similarly treated
littermate donor. Values obtained from the two clearance
periods were averaged and used for analysis. RPP was then
adjusted to approximately 160 mm Hg in both strains by
releasing the aortic clamp above the renal artery, and if neces-
sary, partially occluding the one below the renal artery. After a
15-minute equilibration period, the second clearance study was
performed in the same manner as the first clearance study. Then
RPP was increased to approximately 190 mm Hg in both strains
by tightening the clamp below the renal artery and occluding the
mesenteric and celiac arteries. After another 15-minute equili-
bration period, the third clearance study was also carried out in
the identical manner. Therefore, in the L-NMMA administered
WKY rats, their RPP levels were adjusted around 130, 160, and
190 mm Hg, whereas in the following groups, they were
adjusted around 110, 130, and 160 mm Hg.
L-arginine groups (mean body weight: WKY277 4g, SHR
280 5 g). A substrate of NO synthase, L-arginine (3 mg/minI
kg, Sigma Chemical Co.) was added to the saline vehicle instead
of L-NMMA. This ratio of L-argmine to L-NMMA was decided
from previous in vivo and in vitro studies [18, 19]. The other
experimental protocol was the same as the L-NMMA groups;
RPP was adjusted around 130, 160, and 190 mm Hg in SHR and
110, 130, and 160 mm Hg in WKY, respectively.
L-NMMA + L-argifline groups (mean body weight: WKY275
5 g, SHR 270 5 g). In this subset of groups, both L-NMMA
(1 mg/mm/kg) and L-arginine (3 mg/mm/kg) were added to the
saline vehicle and infused simultaneously. The other experi-
mental protocol and RPP levels were the same as the L-argirnne
groups.
Control groups (mean body weight: WKY28I 5 g, SHR 276
5 g). In the control SHR and WKY rats, the saline vehicle
described in Surgical preparation was infused at the same rate
throughout the study. After the surgery and the 60-minute
equilibrium period, another 15-minute equilibration period was
allowed instead of the lead-in period in the previous groups.
Clearance studies were then performed in the same fashion as in
the L-arginine groups.
Urinary NO2 /N0j excretion in SHR and WKY rats
Experiments were designed to study the response of NO
release in normotensive and hypertensive rats. Urinary excre-
tion of NO metabolites (NO2 and/or NO3—) was measured as
an index of NO release. Twenty-four SHR and 24 WKY rats
were divided into four groups (N = 6/group), respectively. They
were instrumented as described in Surgical preparation, except
that femoral artery was not cannulated and the aortic clamps
were not placed.
After the surgical preparation, rats were allowed to equili-
brate for 60 minutes. In the first groups of SHR (mean body
weight: 276 4 g) and WKY (278 5 g), L-NMMA (1
mg/mm/kg) was added to the infusate and continued throughout
the rest of the experiment. In the second groups (SHR 281 S
g, WKY 279 4 g), L-arginine (3 mg/mm/kg) was added to the
infusate instead of L-NMMA. In the third groups (SHR 271 5
g, WKY 274 4 g), both L-NMMA (1 mg/mm/kg) and L-argi-
nine (3 mg/mm/kg) were added to the infusate at the same time.
Rats were allowed to equilibrate for 20 minutes, then urine was
collected for 30 minutes and systemic blood pressure was
measured. Time control SHR (276 5 g) and WKY (280 5 g)
rats were prepared in a similar fashion and given the saline
vehicle throughout the study. They were allowed to equilibrate
for 80 minutes before the 30-minute clearance period.
Analysis and statistics
Urine volume was measured gravimetrically, and urine flow
rate was factored per gram kidney weight. Sodium concentra-
tions were measured with a flame photometer. Glomerular
filtration rate (GFR) and renal plasma flow (RPF) were calcu-
lated as the ratio of the urine/plasma concentration of inulin and
PAH multiplied by the urine flow rate, respectively. Filtration
fraction (FF) was calculated as the ratio of GFR to RPF.
NO2/N03 concentration was measured by automated system
TCI-NOX 1000 (Tokyo Kasei Kogyo Co., Tokyo, Japan) based
on colorimetric methods [20, 21]. The intra-assay coefficient of
variation was 0.35%.
Values are given as means SEM. Statistical significance of
differences in individual values were checked using analysis of
variance or unpaired t-tests, as appropriate. Linear regression
analysis was used to calculate the slopes of the lines relating
sodium excretion and RPP. Differences in the slopes of these
lines were compared using an unpaired t-test. Significance of
difference in urinary N02/N03 excretion was determined
using two-way analysis of variance. P < 0.05 was acknowl-
edged as statistically significant.
Results
The effects of renal perfusion pressure and L-NMMA or
L-arginine infusion on renal function were summarized in Table
1. In both control SHR and control WKY, glomerular filtration
rate was preserved almost constant in the range of renal
perfusion pressure studied (l30—l90 mm Hg in SHR and
1 10— 160 mm Hg in WKY). This autoregulation of glomerular
filtration rate was not affected by the administration of either
L-NMMA or L-arginine. Moreover, the absolute value of the
glomerular filtration rate did not differ significantly between the
two strains. Renal plasma flow was also well autoregulated in
both SHR and WKY control rats. However, with the adminis-
tration of L-NMMA, the renal plasma flow was significantly
reduced in both strains. When compared with the respective
control rats at the same blood pressure level (160 mm Hg in
SHR and 130 mm Hg in WKY), the absolute values were as low
as 62% in SHR and 56% in WKY. As a result, L-NMMA
infusion caused a significant rise in filtration fraction in both
strains (Table 1). Administration of L-arginine alone did not
cause any significant effect on renal plasma flow and filtration
fraction, however, when infused simultaneously, L-arginine
effectively reversed tnese hemodymanic changes caused by
L-NMMA infusion.
Figure 1 illustrates the effect of L-NMMA administration on
the pressure-natriuresis relationship of both strains. As re-
ported previously [22, 23], the pressure-natriuresis curve of
Renal perfusion pressure, mm Hg
Fig. 1. Effect of L-NMMA administration on the pressure-natriuresis
relationship in WKY and SHR rats. Symbols are: (0) control WKY;
(D) WKY treated with L-NMMA (1 mg/mm/kg); (•) control SHR; (U)
SHR treated with L-NMMA (1 mg/mm/kg). Values are means SEM.
*p < 0.05 from control WKY at the same RPP level; tslope of line in
L-NMMA treated WKY is significantly (P < 0.05) smaller than slope of
line in control WKY.
SHR was shifted rightward and its slope was more flattered
compared to that of WKY (0.08 tEq/min/g kidney wtlmm Hg
vs. 0.21 Eq/min/g kidney wt/mm Hg, P < 0.05), showing
blunted natriuresis response to the elevation of renal perfusion
pressure. L-NMMA administration caused a significant blood
pressure elevation in both strains, however, when renal perfu-
sion pressure was adjusted at equivalent levels by the aortic
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Table 1. Effects ofperfusion pressure and L-NMMA or L-arginine infusion on renal function of SHR and WKY rats
SHR WKY
L-NMMA
RPP mm Hg 134 2 161 4 190 3 132 2 158 3 183 3
Unne flow pi/minig kidney wt 17 4 27 4 39 9 40 9 59 8" 88 l3
GFR ml/min/g kidney wt 1.3 0.1 1.4 0.2 1.4 0.1 1.3 0.2 1.5 0.2 1.5 0.2
RPF mllmin/g kidney wt 2.5 0.3" 2.6 0.3" 3.0 0.2" 2.5 0.2" 2.5 0.3" 2.6 0.3
FF 0.58 0.03" 0.60 004b 0.49 005b 0.60 0.05" 0.67 005b 0.64 0.07
L-argifline
RPP mm Hg 137 2 162 4 191 4 116 2 135 3 155 2
Urine flow pi/minig/kidney wt 21 3 42 5 71 15 39 7 62 7" 87 1l
GFRm1/min/gkidneywt 1.3±0.1 1.3±0.1 1.3±0.1 1.3±0.1 1.4±0.1 1.4±0.1
RPF mI/minlg kidney wt 4.3 0.3 4.3 0.3 4.6 0.3 4.5 0.3 4.4 0.2 4.6 0.3
FF 0.30 0.02 0.03 0.02 0.28 0.03 0.29 0.02 0.32 0.01 0.31 0.02
L-NMMA + 1-arginine
RPP mm Hg 134 2 162 3 193 3 113 2 134 2 160 3
Urine flow pi/minig kidney wt 18±4 33±4 53 32±6 48±6 78 ioa
GFR mI/minig kidney wt 1.3 0.2 1.3 0.2 1.4 0.2 1.2 0.2 1.4 0.1 1.4 0.2
RPF ml/min/g kidney wt 3.7 0.4 4.0 0.3 3.9 0.4 4.1 0.3 4.0 0.3 4.2 0.4
FF 0.34 0.04 0.33 0.03 0.35 0.04 0.31 0.02 0.34 0.04 0.33 0.04
Control
RPP mm Hg 138 2 163 4 195 3 115 2 132 ia 157 2
Urine flow pi/minig kidney wt 19 3 29 5 48 5 30 7 45 4 85 ioa
GFR ml/min/g kidney wt 1.2 0.1 1.2 0.1 1.4 0.2 1.3 0.2 1.3 0.1 1.4 0.2
RPF ml/min/g kidney wt 3.9 0.3 4.2 0.4 4.4 0.3 4.2 0.4 4.5 0.3 4.5 0.4
FF 0.31 0.02 0.30 0.04 0.33 0.03 0.31 0.02 0.29 0.02 0.30 0.03
Values are means SEM.
a P < 0.05 statistically significant from the value obtained at the lowest renal perfusion pressure
b P < 0.05 statistically significant from controls with identical RPP levels
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Fig. 2. Effect of L-arginine administration on the pressure-natriuresisFIg. 3. Effect of simultaneous administration of L-NMMA and L-argi-
relationship in WKY and SHR rats. Symbols are: (0) control WKY; nine on the pressure-natriuresis relationship in WKY and SHR rats.(0) WKY treated with L-arginine (3 mg/mm/kg); (•) control SHR; (U) Symbols are: (0) control WKY; (0) WKY treated with L-NMMA (I
SHR treated with L-arglnine (3 mg/mm/kg). Values are means SEM. mg/mm/kg) + 1-arginine (3 mg/mm/kg); (•) control SHR; (U) SHR
< 0.05 from control SHR at the same RPP level, f slope of line in treated with L-NMMA (I mg/mm/kg) + L-arginine (3 mg/mm/kg).
L-arginine treated SHR is significantly (P < 0,05) greater than slope of Values are means SEM.
line in control SHR.
clamping, it induced decreased sodium excretion in WKY, but
not in SHR. This antinatriuretic effect of L-NMMA resulted in
the rightward shift of the pressure-natriuresis curve of WKY,
P<0.001 P<0.05 P<0.001 P<0.001
200 I I I
and its slope became significantly less steep compared with that
of control WKY (0.12 pEq/minlg kidney wt/mm Hg vs. 0.21
EE 180
Eq/min/g kidney wt/mm Hg, P < 0.05). On the contrary, when
L-arginine alone was infused, its natriuretic effect was statisti- * *
cally significant only in SHR (Fig. 2). Compared with control 160
SHR, the pressure-natriuresis curve of L-argirnne infused SHR
was shifted to the left and its slope was elevated significantly
(0.16 Eq/niinIg kidney wtlmm Hg vs. 0.08 Eq/min/g kidney
g 140
wt/mm Hg, P < 0.)5). Therefore, the impaired pressure-
natriuresis of SHR was improved by L-arginine, but was not
blunted further by L-NMMA. In contrast, the pressure-natri- 120
uresis response of WKY was significantly deteriorated by
L-NMMA, however, L-arginine did not enhance it further.
Figure 3 illustrates the result of the simultaneous infusion of
L-NMMA and L-arginine. The concomitant administration
nearly abolished either effect of L-NMMA or L-arginine, and the
pressure-natriuresis curves of these co-infused animals did not
differ significantly from those of respective controls.
Figure 4 shows the effects of L-NMMA and/or L-arginine
administration on systemic blood pressure in both strains.
Addition of L-NMMA to the infusate evoked marked blood
pressure elevation in both SHR (155 3 mm Hg vs. 170 5 mm
Hg, P < 0.05) and WKY (138 1 mm Hg vs. 157 6 mm Hg,
P < 0.01). L-argirnne lowered systemic blood pressure signifi-
cantly in WKY (131 2 mm Hg, P < 0.05), but the difference
did not reach statistical significance in SHR (149 3 mm Hg, P
= 0.07). When infused simultaneously, L-NMMA and L-argi-
nine had no effect on systemic blood pressure in either SHR
(159 3mm Hg, P = 0.17)or WKY (139 2mm Hg, P =0.42).
The effects of L-NMMA and/or L-arginine administration on
urinary NO2/NO excretion are shown in Figure 5. In the
control groups, there was a difference in urinary excretion of
ii
Control NMMA L-arginine NMMA
+
L-arginine
Fig. 4. Mean SEM values for mean blood pressure in WK Y and SHR
rats. Control groups received vehicle only, while L-NMMA, L-arginme,
and L-NMMA + L-arginine groups received vehicle plus L-NMMA (1
mg/mm/kg), L-arginine (3 mg/mm/kg), or both. Symbols are: (0) WKY;
(U) SHR. ', ** P < 0.05, 0.01 vs. respective control.
N02/N03 between SHR and WKY (10.4 1.0 nM/min/g
kidney wt vs. 7.7 0.6 nM/minlg kidney wt, P < 0.05).
However, when two-way analysis of variance was applied to
the overall data, the difference was not significant (P = 0.10).
Two-way analysis of variance also indicated that there were
differences in urinary N02/N03 excretion among the
L-NMMA, L-arginine, L-NMMA + L-arginine, and control
groups (P < 0.001), and there was no interaction between
treatment and strain of rat (P = 0.66). L-NMMA administration
caused significant decrease in NO2/NO3 excretion in both
SHR (5.5 1.0 nM/min/g kidney wt, P < 0.01) and WKY (4.4
0.8 nM/min/g kidney wt, P < 0.01). In contrast, addition of
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the effects of L-NMMA and/or L-arglnine on renal plasma flow
I and glomerular filtration rate are consistent with those of
previous studies [15, 19, 26—28], recent studies have shown that
administration of a smaller amount of L-NMMA did not induce
any significant changes in sodium excretion in dogs [29, 30].
These differences may be due to differences in animal species,
doses of L-NMMA [31], or experimental designs. The presence
of intact renal nerves and hormonal responses may have
antagonized the sodium-retentive effect of L-NMMA in those
studies [8]. However, the possibility that some of the hormones
infused in this study may have the potential to alter NO
synthesis or its action directly must also be considered [32].
L-arginine infusion into WKY failed to enhance their pres-
sure-natriuresis curve, and L-NMMA infusion did not blunt that
of SHR. The possibility that the doses used were too small must
Control NMMA L-arginine NMMA be considered first. However, this possibility seems low, be-
+ cause the urinary excretion of NO metabolites was significantly
decreased or increased by infusion of the same dose of
i-NMMA or L-arginine, respectively. In addition, the doses
used in our study were equivalent to those employed in previ-
ous in vivo studies [26, 33]. Therefore, our observation that
administration of L-arginine to WKY caused a significant in-
crease in the urinary NO2/N03 excretion without further
enhancement of the pressure-natriuresis response may indicate
that under physiological conditions, WKY are able to release
sufficient NO to maintain their normal pressure-natriuresis
response. On the other hand, in SHR, L-NMMA administration
did not blunt the pressure-natriuresis response further, proba-
bly because other mechanisms compensated the pressure-
natriuresis response in this strain.
NO is synthesized from L-arginine, and its metabolites are
excreted into urine as N02/NO3 [34, 35]. At present, it is
impossible to measure NO in the blood, because its half life is
in the order of only seconds and many substances including
hemoglobin interfere with its measurement. In contrast, NO2—!
N03 is stable in the blood or urine, and its measurement is
feasible [21]. Although the question whether urinary NO2-!
NO3 — reflects mainly systemic or local generation of NO
Discussion remains unanswered, measurement of urinary N02/NO3
In this study, we examined the role of NO in the regulation of may, at least in part, estimate NO release.
the pressure-natriuresis response in both normotensive and We have demonstrated in this study that the deficiency in NO
hypertensive rats. L-NMMA infusion markedly blunted the system may be one of the responsible factors for the impaired
pressure-natriuresis curve of WKY, while L-arginine adminis- pressure-natriuresis in SHR. When we compare the urinary
tration improved that of SHR. These effects on the pressure- excretion of NO2/NO3 between the control SHR and WKY
natriuresis response are considered to be NO mediated, be- (Fig. 5), the results are seemingly puzzling, because SHR
cause they were effectively reversed by the concomitant excretes similar amount of NO metabolites as WKY does.
infusion of L-NMMA and L-arginine. In all cases, there were no However, in our recent study, we have shown that urinary
changes in the glomerular filtration rate. This finding indicates NO2/N03 excretion was increased by mechanical blood
that it was not the filtered sodium load on the glomeruli but its pressure elevation and this increase was abolished by L-NMMA
handling thereafter that was altered, suggesting that NO mod- [20]. Therefore, the marked difference in mean blood pressure
ulates tubular sodium reabsorption. It has been suggested that between the two strains (Fig. 4) must be considered in the
suppression of tubular sodium reabsorption due to interstitial assessment of the basal NO2/NO3 excretion.
hydrostatic pressure elevation is essential to the mechanism of It is interesting to note that when two-way analysis of
pressure-natriuresis response, and that papillary hemodynam- variance was applied to the overall data, the difference of
ics plays a critical role in the regulation of the interstitial urinary NO2/NO3 excretion between SHR and WKY was not
hydrostatic pressure [24, 25]. It is therefore logical to propose significant. This indicates that in adult WKY and SHR, endo-
that NO, with its prominent vasodilating action, participates in thelial NO synthesis respond similarly to NO inhibition or
the pressure-natriuresis response through regulation of intra- stimulation. In spite of this fact, their pressure-natriuresis
renal blood flow distribution. Although our results concerning curves changed differently in these conditions. Therefore, in
NS NS NS
I I I30
25
20
15
10
5
0
L-arginine
Fig. 5. Mean SEM values for urinary N02/NO3 excretion in WKY
and SHR rats. Control groups received vehicle only, while L-NMMA,
L-arginine, and L-NMMA + L-arginine groups received vehicle plus
L-NMMA (1 mg/mm/kg), L-arginine (3 mg/mm/kg), or both. Symbols
are: (D) WKY; (U) SHR. , P <0.01,0.001 vs. respective control.
L-arginine increased urinary excretion of N02/NO3 more
than twofold in both SHR (21.5 3.5 nM/min/g kidney wt, P <
0.01) and WKY (18.8 2.4 nM/min/g kidney weight, P < 0.001).
From these data, it was demonstrated that the urinary excretion
of NO metabolites was significantly decreased or increased by
the infusion of the same dose of L-NMMA or L-arginine which
were employed in the pressure-natriuresis studies. It was also
confirmed that addition of three times larger dose of L-arginine
(3 mg/mm/kg) to L-NMMA (1 mg/mm/kg) almost reversed the
excretion of urinary NO metabolites to the control levels (SHR:
12.1 1.3 nM/min/g kidney wt, P = 0,18; WKY: 10.2 1.5
nM/min/g kidney wt, P = 0.07).
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SHR, it is likely that their ability of NO synthesis was preserved
while their renal response to NO was impaired.
Previous studies from our laboratory have demonstrated the
importance of the intrarenal renin-angiotensin system in the
pressure-natriuresis response in SHR [2]. Since a growing
amount of evidence suggests an intimate relations between the
renin-angiotensin system and NO [36—381, it is possible that the
former modulates the pressure-natriuresis response through the
latter. Further, the vascular endothelium is also able to generate
vasoactive substances like endothelin and its interaction with
NO has been recognized [391. Combining these findings, it is
likely that in the kidney, complex interactions among NO,
endothelin, and the renin-angiotensin system exist, affecting the
pressure-natriuresis response. However, it has been reported
that in dogs, inhibition of angiotensin-converting enzyme did
not influence the renal responses to NO blockade [28]. There-
fore, further studies are absolutely necessary before a conclu-
sion can be drawn.
In summary, we have demonstrated the importance of NO in
the maintenance of the normal pressure-natriuresis response.
Dysfunction of this system is partly responsible for the impaired
pressure-natriuresis in SHR. These data suggest that distur-
bance in endothelial control of the renal function could play
some role in the pathogenesis of hypertension.
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